Crossmark

Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation—a prospective, observational study

Published Online: 2020-10-06

Published Print: 2020-12

Authors

Andréasson, Kristofer https://orcid.org/0000-0001-7021-2541
Neringer, Karl

Wuttge, Dirk M.

Henrohn, Dan

Marsal, Jan

Hesselstrand, Roger
Funding

Funding for this research was provided by:

Anna-Greta Crafoord Foundation

Svenska Läkaresällskapet (SLS-784201)

Reumatikerförbundet (R-742291)

Stiftelsen Ulla och Roland Gustafssons Donationsfond
License Information

Text and Data Mining valid from 2020-10-06

Version of Record valid from 2020-10-06
More Information

Article History

Received: 17 May 2020

Accepted: 22 September 2020

First Online: 6 October 2020

Ethics approval and consent to participate

: This study was approved by the Swedish Ethical Review Authority (Dnr 2018/490) and the Swedish Medical Products Agency (EudraCT 2018-002105-54) and prospectively registered at(NCT03678987, posted September 20, 2018). All participants gave their written informed consent prior to entering the study. The study was conducted in accordance with the Declaration of Helsinki.

: Not applicable.

: All authors declare no competing interests.

Document is current